sonidegib: Clinical Trials

21 trials of sonidegib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 21 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Completed 17, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 23Completed 2, Terminated 1

Follow sonidegib: new trials by email Literature Review of sonidegib trials Research Report on sonidegib

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Phase 1Active not recruitingMayo Clinic362020-02-132026-03-18
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase 1CompletedSt. Jude Children's Research Hospital682018-03-052024-05-31
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
LDE225 - Recurrent Ovarian Cancer
Phase 1CompletedUniversity of Alabama at Birmingham152014-09-012026-02-09
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Docetaxel, Prednisone, LDE225 - Prostate Cancer
Phase 1WithdrawnMartin Gutierrez2014-07-012019-06-19
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
LDE225 - Hepatocellular Carcinoma, Cirrhosis
Phase 1CompletedJason K. Sicklick, M.D.92014-07-012019-03-05
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
LDE225, Docetaxel - Advanced Breast Cancer
Phase 1CompletedSpanish Breast Cancer Research Group122014-05-012023-04-03
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Azacitidine, Decitabine, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome
Phase 1CompletedMayo Clinic632014-05-012019-10-30
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
LDE225 - Graft Versus Host Disease
Phase 1TerminatedMassachusetts General Hospital172014-04-012018-03-19
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
LDE225 - Prostate Cancer
Phase 1CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins142014-04-012019-03-07
LDE225 and Paclitaxel in Solid Tumors
LDE225, Paclitaxel - Solid Tumor, Ovarian Cancer
Phase 1CompletedSwiss Cancer Institute302013-09-012019-12-06
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
LDE225, INC424 - Primary Myelofibrosis, Thrombocytosis
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals502013-05-082020-04-15
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
LDE225, Wafarin, Bupropion - Advanced Solid Tumor
Phase 1CompletedNovartis Pharmaceuticals1142013-04-012020-12-19
Effect of Hepatic Impairment on LDE225..
LDE225 - Normal Hepatic Function, Impaired Hepatic Function
Phase 1CompletedNovartis Pharmaceuticals332013-03-012020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
LDE225, BKM120 - Dose Escalation, Safety
Phase 1CompletedNovartis Pharmaceuticals1202012-07-012020-12-19
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
LDE225, Etoposide and Cisplatin - Lung Cancer
Phase 1CompletedMemorial Sloan Kettering Cancer Center192012-04-012017-08-17
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Nilotinib + LDE225 - Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Phase 1CompletedNovartis Pharmaceuticals112012-01-012020-12-09
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
LDE225-600mg, Gemcitabine, nab-paclitaxel - Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins232011-12-272020-01-22
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan - Pancreatic Cancer
Phase 1CompletedMassachusetts General Hospital392011-12-012020-08-04
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
LDE225 - Medulloblastoma, Rhabdomyosarcoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals762011-02-012017-03-20
An East Asian Study of LDE225
LDE225 - Advanced Solid Tumor Cancers, Medulloblastoma
Phase 1CompletedNovartis Pharmaceuticals452010-10-012020-12-19

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Medulloblastoma (4)  ·  Astrocytoma (2)  ·  Carcinoma, Basal Cell (2)  ·  Glioblastoma (2)  ·  Glioma (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Ovarian Neoplasms (2)  ·  Polycythemia Vera (2)  ·  Primary Myelofibrosis (2)  ·  Prostatic Neoplasms (2)  ·  Recurrence (2)  ·  Thrombocythemia, Essential (2)  ·  Blood Coagulation Disorders (1)  ·  Blood Platelet Disorders (1)

Sponsors

Novartis Pharmaceuticals (8)  ·  Massachusetts General Hospital (2)  ·  Mayo Clinic (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  Jason K. Sicklick, M.D. (1)  ·  Martin Gutierrez (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Spanish Breast Cancer Research Group (1)  ·  St. Jude Children's Research Hospital (1)  ·  Swiss Cancer Institute (1)  ·  University of Alabama at Birmingham (1)

Countries

United States (16)  ·  Spain (5)  ·  Canada (4)  ·  Germany (4)  ·  Italy (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Belgium (3)  ·  France (3)  ·  Switzerland (2)  ·  Bulgaria (1)  ·  Denmark (1)  ·  Hong Kong (1)  ·  Ireland (1)  ·  Israel (1)

Top investigators

Ana De Jesus-Acosta, MD (1)  ·  Anastasios Stathis, MD (1)  ·  Aref Al-Kali (1)  ·  Charles A Leath, III, MD, MSPH (1)  ·  Charles Rudin, MD (1)  ·  Cristiana Sessa, Prof Dr med (1)  ·  Emmanuel Antonarakis, M.D. (1)  ·  Giles W. Robinson, MD (1)  ·  Jason K. Sicklick, MD (1)  ·  Jeffery W Clark, MD (1)  ·  Mojun Zhu, M.D. (1)  ·  Yi-Bin Chen, MD (1)

Results publications

PMID 27467121, PMID 29296838, PMID 29948356, PMID 30042390, PMID 32634234, PMID 32736411

NIH funding

2008 (1), P30CA015083 (1)